dostarlimab sold brand name jemperli monoclonal antibody used anticancer medication treatment endometrial dostarlimab programmed death monoclonal common side effects reported us include fatigueasthenia nausea diarrhea anemia additional side effects reported european union include vomiting joint pain itching rash fever hypothyroidism low levels thyroid dostarlimab approved treatment endometrial cancer united states european union april based garnet trial dostarlimab gained accelerated approval us food drug administration fda april full approval february united states dostarlimab indicated treatment adults mismatch repair deficient dmmr recurrent advanced endometrial cancer determined fdaapproved test progressed following prior treatment platinumcontaining platinumbased agents cisplatin carboplatin oxaliplatin mainstays treatment comes cancer chemotherapy also indicated treatment solid european union dostarlimab indicated monotherapy treatment adults mismatch repair deficient dmmrmicrosatellite instabilityhigh msi h recurrent advanced endometrial cancer progressed following prior treatment platinumcontaining august us food drug administration fda granted accelerated approval dostarlimab adults mismatch repair deficient dmmr recurrent advanced solid tumors determined fdaapproved test progressed following prior treatment satisfactory alternative treatment july fda expanded indication dostarlimab combination carboplatin paclitaxel followed singleagent dostarlimab treatment primary advanced recurrent endometrial cancer mismatch repair deficient determined fdaapproved test microsatellite efficacy evaluated ruby randomized multicenter doubleblind placebocontrolled efficacy assessed prespecified subgroup participants dmmrmsih primary advanced recurrent mmrmsi tumor status determined local testing assays ihc pcr ngs central testing ihc using ventana mmr rxdx panel local results endometrial cancer disease cancerous cells reside lining uterus four stages endometrial cancer ranging staying settled endometrium cancer spreading organs disease treated discovered beginning chemoresistant msihigh tumors studies conducted dostarlimab pembrolizumab display promising results tumors reacting well solid tumors tumors contain liquid cysts occur many places including bones muscles organs common types solid tumors sarcomas dostarlimab used treat recurrent advance tumors patients tried alternative treatment serious adverse reactions patients included sepsis acute kidney injury urinary tract infection abdominal pain fever immunemediated adverse reactions occur including pneumonitis colitis hepatitis endocrine disease endocrinopathies common side effects reported taking medication trial dyspnea asthenia fatigue symptoms overdose similar side effect profile medication could involve significant immunemediated dostarlimab monoclonal antibody binds block binding ligands remove inhibition immune causes risk immunemediated adverse reactions severe fatal occur part body organs examples immunemediated adverse reactions include immunemediated pneumonitis colitis hepatitis adrenal insufficiency hypophysitis thyroid disorders nephritis renal dysfunction dermatologic dostarlimab cause harm death fetus occur immune systems reaction fetus examination mechanism animal dostarlimab human immunoglobulin g could permeate placental may risk harm developing fetus drug may passed data available regarding presence dostarlimab dostarlimab causes mild moderate elevations serum aminotransferase alkaline phosphatase serum alt elevation five times normal range occurs people treated dostarlimab develop immune related liver symptoms liver injury acute liver failure include jaundice pain upper right abdomen ascites nauseavomiting disorientation dostarlimab humanized monoclonal antibody derived mouse antibody humanized via complementarity determining region cdr serum halflife antibodies included nivolumab opdivo pembrolizumab keytruda uses many different types cancers include classical hodgkin lymphoma renal cell carcinoma breast another antibody cemiplimab libtayo approved treatment squamous cell carcinoma basal cell carcinoma nonsmall cell lung dostarlimab binds receptor high affinity block activity ligands coinhibitory receptor important checkpoint protein regulating tcell constantly stimulated ligands highly expressed cancer cells allows cancer cells dodge tcell mediated immune therefore blocking binding ligands allow tcells function normally prevent tumor cells bypassing immune mouse tumor models shown inhibiting activity decreased tumor garnet trial dostarlimab achieved favorable results decreasing size tumor endometrial study observed people endometrial cancer seven different countries size tumor reduced population dostarlimab exhibits better efficacy inhibitors avelumab durvalumab dmmr advanced endometrial efficacy drug measured response rate dostarlimab undergoing phase iii phase iii clinical manufacturer tesaro announced preliminary successful results phase iii garnet garnet study announced dostarlimab promising potential treat specific subset individuals recurrent advanced endometrial april dostarlimab approved treatment recurrent advanced endometrial cancer mismatch repair deficient dmmr genetic abnormalities disrupt dna repair individuals previously treated platinumcontaining april us food drug administration fda granted accelerated approval dostarlimabgxly jemperli efficacy evaluated based cohort garnet trial multicenter multicohort openlabel trial participants advanced solid fda approved dostarlimab based evidence garnet trial participants advanced recurrent endometrial cancer shown mismatch repair deficient dmmr certain types chemotherapy work longer cohort used approved indication conducted sites countries north america early clinical study dostarlimab reported remission rate patients rectal cancer mismatch repair deficiency type genetic mutation affects february fda approved dostarlimabgxly jemperli glaxosmithkline llc adults mismatch repair deficient dmmr recurrent advanced endometrial cancer determined fdaapproved test progressed following prior platinumcontaining regimen setting candidates curative surgery dostarlimab international nonproprietary name united states adopted name february committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting conditional marketing authorization medicinal product jemperli intended treatment certain types recurrent advanced endometrial applicant medicinal product gsk ireland dostarlimab approved medical use european union april united states dostarlimab costs around per among insured medicaid insurance less likely receive full care gynecologic insured private insurance still experience economical hardships getting uninsured patients tend get screened regularly results late diagnosis immune activation dostarlimab ibalizumab httpsenwikipediaorgwikidostarlimab